<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/E7910513-EA16-41B2-A0C0-7F49C936A4BF"><gtr:id>E7910513-EA16-41B2-A0C0-7F49C936A4BF</gtr:id><gtr:name>University of Wales</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>University Registry</gtr:line1><gtr:line2>King Edward VII Ave</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF10 3NS</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E7910513-EA16-41B2-A0C0-7F49C936A4BF"><gtr:id>E7910513-EA16-41B2-A0C0-7F49C936A4BF</gtr:id><gtr:name>University of Wales</gtr:name><gtr:address><gtr:line1>University Registry</gtr:line1><gtr:line2>King Edward VII Ave</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF10 3NS</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C7C0FC1F-2464-4404-9921-CAFD2EB08C64"><gtr:id>C7C0FC1F-2464-4404-9921-CAFD2EB08C64</gtr:id><gtr:firstName>Eddie</gtr:firstName><gtr:otherNames>Chung</gtr:otherNames><gtr:surname>Wang</gtr:surname><gtr:orcidId>0000-0002-2243-4964</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0300180"><gtr:id>03C23C86-B296-421F-8176-D9C44F09E14C</gtr:id><gtr:title>The role of death receptor 3 in peripheral CD8+ T cell function</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300180</gtr:grantReference><gtr:abstractText>Death Receptor 3 (DR3) is a member of the tumour necrosis factor receptor superfamily of proteins that are involved in regulation and development of the immune response. However, the specific biological function of DR3 has remained obscure. Our preliminary research has identified a role for DR3 in the development and function of CD8+ T cells. CD8+ T cells represent one of the cytotoxic arms of the immune response, generating cells that kill virus-infected and cancerous targets. CD8+ T cells can also be responsible for autoimmunity when their regulation is disrupted. This project is designed to define the role played by DR3 in CD8+ T cell function. In so doing, we may learn how to manipulate the CD8+ T cell response, which is a major target for immunotherapies against virus infections, cancers and autoimmune disease.</gtr:abstractText><gtr:technicalSummary>Of the death-domain containing tumour necrosis factor receptor (TNFR) superfamily members, death receptor 3 (DR3) is the closest relative to TNFR1. Like TNFR1, the in vitro over-expression of DR3 can lead to either cell death or cell survival/activation. However, little is known of the in vivo role of DR3. Previously, I have generated mice deficient for the DR3 gene (DR3ko), which showed a defect in the removal of self-reactive CD8+ thymocytes. Recently, I have identified more phenotypic differences in peripheral DR3koCD8+ T cells, including: (i) decreased CD8+ proliferation following stimulation with certain, polyclonal T cell activators; (ii) decreases in the proportion of CD8+ T cells expressing memory markers. CD8+ T cells represent the cytotoxic arm of the adaptive immune response, killing target cells in a MHC I-restricted manner. Impairment of CD8+ T cell regulation through loss of DR3 may lead to dysfunctional CD8+ T cells and disrupted immunity to infections and cancer or altered susceptibility to autoimmunity. This proposal is designed to characterise the defects in DR3koCD8+ T cells and investigate whether they result in CD8+ immune dysfunction in vivo. Specifically, there are 5 major experimental aims:
AIM I. To characterise the in vitro proliferative defect in murine DR3koCD8+ T cells 
AIM II. To investigate the in vivo role of DR3 in CD8+ T cell proliferation and homeostasis 
AIM III. To investigate the in vivo role of DR3 in CD8+ T cell-dependent anti-viral immunity 
AIM IV. To investigate the in vivo role of DR3 in the generation of self-reactive CD8+ T cells
AIM V. To define the role of DR3 in CD8+ T cell function in man</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-16</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-08-17</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>643575</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Asthma</gtr:description><gtr:id>D3142480-6771-4133-8B42-9C1F9D461E71</gtr:id><gtr:impact>Successful grant funding - BBSRC/GSK CASE Studentship awarded in 2009</gtr:impact><gtr:partnerContribution>Intellectual input</gtr:partnerContribution><gtr:piContribution>Staff, reagents and intellectual input</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>EAE</gtr:description><gtr:id>A65A4404-C9D7-45EE-87FB-1D07CBD2A96B</gtr:id><gtr:impact>Publications - PMID: 18571443</gtr:impact><gtr:partnerContribution>Publication</gtr:partnerContribution><gtr:piContribution>Reagents and intellectual input</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cardiff University School of Medicine</gtr:department><gtr:description>Arthritis</gtr:description><gtr:id>FC334D62-6303-46E2-8569-EE6CBEECF20F</gtr:id><gtr:impact>Publications - PMID: 18824582 Grants - ARC PhD studentship awarded in 2009</gtr:impact><gtr:partnerContribution>Joint publication</gtr:partnerContribution><gtr:piContribution>Staff, intellectual input and funding for expts</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medical Biochemistry and Immunology</gtr:department><gtr:description>MCMV</gtr:description><gtr:id>2DF6F64F-405E-485E-8523-EC52A67138AA</gtr:id><gtr:impact>Successful grant funding - MRC Project Grant awarded in 2009</gtr:impact><gtr:partnerContribution>Intellectual input and reagents</gtr:partnerContribution><gtr:piContribution>Staff, reagents, intellectual input</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Biological Sciences Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>Neurology</gtr:description><gtr:id>04C470B8-5E60-4AC5-86D1-0EB01451353D</gtr:id><gtr:impact>Publication - PMID: 18287561</gtr:impact><gtr:partnerContribution>Publication</gtr:partnerContribution><gtr:piContribution>Reagents and intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medical Biochemistry and Immunology</gtr:department><gtr:description>Lung</gtr:description><gtr:id>C2A0AAC2-E474-4C55-A108-96C24B3FE273</gtr:id><gtr:impact>Successful grant funding - BBSRC/GSK CASE Studentship awarded in 2009</gtr:impact><gtr:partnerContribution>Intellectual input</gtr:partnerContribution><gtr:piContribution>Reagents and intellectual input</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Poster at MRC Showcase</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>40C9918A-C3C4-41D8-A1DB-9A1142EF2FA6</gtr:id><gtr:impact>Poster at the MRC Immunotherapies and Vaccines Showcase at the Sanger Institute, Cambridge

Runner-up Industry Poster Award and some interest from Pharma, though no funding as yet</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>534818</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4A1BB05D-F00A-474A-96B1-1912C0D25297</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>97110</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE Studentship (GSK)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>F9A239B4-6E21-48F6-B3BA-74CEC96F4F58</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80530</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARC PhD Studentship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>541B9861-DFAD-4488-B839-2E09F0E727BD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>188888</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Collaboration Grant</gtr:description><gtr:end>2009-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DCEF532F-F0AF-44BF-A9B2-F267C3B5AA17</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Cardiff University</gtr:fundingOrg><gtr:id>E09C9DC8-E1A9-4919-AE4D-44BEA066B610</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/333F7E45-091F-46B6-99BA-03EA9AB11F58"><gtr:id>333F7E45-091F-46B6-99BA-03EA9AB11F58</gtr:id><gtr:title>Adenovirus vector delivery stimulates natural killer cell recognition.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ab6b817c8e9b654853c81fa652b9c62"><gtr:id>4ab6b817c8e9b654853c81fa652b9c62</gtr:id><gtr:otherNames>Tomasec P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4EF8CDC3-F26A-4501-B065-A2C5825B3776"><gtr:id>4EF8CDC3-F26A-4501-B065-A2C5825B3776</gtr:id><gtr:title>The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6cfc971aa261f45e03d8f66a9f431d6d"><gtr:id>6cfc971aa261f45e03d8f66a9f431d6d</gtr:id><gtr:otherNames>Bull MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD032F6F-9356-4A93-9098-A8B822BA055D"><gtr:id>FD032F6F-9356-4A93-9098-A8B822BA055D</gtr:id><gtr:title>Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf565f746b8db763e1aa7c73394b8ee2"><gtr:id>cf565f746b8db763e1aa7c73394b8ee2</gtr:id><gtr:otherNames>Twohig JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/250F5EE7-C4C0-463D-975A-0725DB28F894"><gtr:id>250F5EE7-C4C0-463D-975A-0725DB28F894</gtr:id><gtr:title>A high-efficiency system of natural killer cell cloning.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a190ea1fc342ec2d7bdfd8fbdc7115c7"><gtr:id>a190ea1fc342ec2d7bdfd8fbdc7115c7</gtr:id><gtr:otherNames>Morris RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29C2BC88-EB33-4DB8-AC37-C7A8AB3DBBCC"><gtr:id>29C2BC88-EB33-4DB8-AC37-C7A8AB3DBBCC</gtr:id><gtr:title>Proliferation and interleukin 5 production by CD8hi CD57+ T cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/66afbdac5bfe2ab6ce81d3eb7c80f079"><gtr:id>66afbdac5bfe2ab6ce81d3eb7c80f079</gtr:id><gtr:otherNames>Chong LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/78D50393-4141-4319-AFD5-33654CE1092F"><gtr:id>78D50393-4141-4319-AFD5-33654CE1092F</gtr:id><gtr:title>Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cb4f1e8c0a6c1979027a09dcd792a65e"><gtr:id>cb4f1e8c0a6c1979027a09dcd792a65e</gtr:id><gtr:otherNames>Jones GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A143A2B9-BD58-4E0B-AF3A-9424D40F6EBD"><gtr:id>A143A2B9-BD58-4E0B-AF3A-9424D40F6EBD</gtr:id><gtr:title>Cytomegalovirus destruction of focal adhesions revealed in a high-throughput Western blot analysis of cellular protein expression.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b6d1b84696df7259b815e773b8f7237"><gtr:id>3b6d1b84696df7259b815e773b8f7237</gtr:id><gtr:otherNames>Stanton RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/300E4E80-C32B-4A95-902E-2E5F1B149892"><gtr:id>300E4E80-C32B-4A95-902E-2E5F1B149892</gtr:id><gtr:title>The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2a6c6144d58e1219cffe64c94ca387bd"><gtr:id>2a6c6144d58e1219cffe64c94ca387bd</gtr:id><gtr:otherNames>Meylan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/26830E86-2D3C-4580-A1E4-D782789EDAD5"><gtr:id>26830E86-2D3C-4580-A1E4-D782789EDAD5</gtr:id><gtr:title>The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/932ff82d19294875266fa547cd2d6b84"><gtr:id>932ff82d19294875266fa547cd2d6b84</gtr:id><gtr:otherNames>Pappworth IY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/28226BA7-6D30-4568-B6C9-546DD1A3E948"><gtr:id>28226BA7-6D30-4568-B6C9-546DD1A3E948</gtr:id><gtr:title>Modulation of natural killer cells by human cytomegalovirus.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d8a2735a3ab0c4d75ed431e7759769ce"><gtr:id>d8a2735a3ab0c4d75ed431e7759769ce</gtr:id><gtr:otherNames>Wilkinson GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F8A94DFE-DD7A-4B26-B512-18C019D8BF9D"><gtr:id>F8A94DFE-DD7A-4B26-B512-18C019D8BF9D</gtr:id><gtr:title>Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9d2a785ff36a73dbabb9a12771c5e73e"><gtr:id>9d2a785ff36a73dbabb9a12771c5e73e</gtr:id><gtr:otherNames>Griffin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C392ABE8-31A4-4C5A-AC53-6CFD042709BA"><gtr:id>C392ABE8-31A4-4C5A-AC53-6CFD042709BA</gtr:id><gtr:title>The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7404c9ae8e2c662f4f25c5bfd1c6a84"><gtr:id>d7404c9ae8e2c662f4f25c5bfd1c6a84</gtr:id><gtr:otherNames>McLaren JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55D6582A-6830-4C69-9000-6C7FE36115AC"><gtr:id>55D6582A-6830-4C69-9000-6C7FE36115AC</gtr:id><gtr:title>Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ab6b817c8e9b654853c81fa652b9c62"><gtr:id>4ab6b817c8e9b654853c81fa652b9c62</gtr:id><gtr:otherNames>Tomasec P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB270014-98E0-425A-8AC4-FAD6B3E556F1"><gtr:id>AB270014-98E0-425A-8AC4-FAD6B3E556F1</gtr:id><gtr:title>Age-dependent maintenance of motor control and corticostriatal innervation by death receptor 3.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf565f746b8db763e1aa7c73394b8ee2"><gtr:id>cf565f746b8db763e1aa7c73394b8ee2</gtr:id><gtr:otherNames>Twohig JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D54F413-C9BE-42AF-BC02-C9DFEC98B098"><gtr:id>5D54F413-C9BE-42AF-BC02-C9DFEC98B098</gtr:id><gtr:title>The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/58e38151138fdd15af992c15175ac172"><gtr:id>58e38151138fdd15af992c15175ac172</gtr:id><gtr:otherNames>Prod'homme V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B5E7989-76D0-42CF-ADBB-789DF029C32A"><gtr:id>0B5E7989-76D0-42CF-ADBB-789DF029C32A</gtr:id><gtr:title>Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eb777def93736c47035c026bce6bd26c"><gtr:id>eb777def93736c47035c026bce6bd26c</gtr:id><gtr:otherNames>Wang EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/681E6A98-98C0-4FF8-ACC3-8BCB7D8CB916"><gtr:id>681E6A98-98C0-4FF8-ACC3-8BCB7D8CB916</gtr:id><gtr:title>Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/effa4fd57fc8e16f84492bc73bbf2c5f"><gtr:id>effa4fd57fc8e16f84492bc73bbf2c5f</gtr:id><gtr:otherNames>Omidvar N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9267428F-5FDF-4C3C-8243-EFA41B244507"><gtr:id>9267428F-5FDF-4C3C-8243-EFA41B244507</gtr:id><gtr:title>Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c345338015db5b28ee186446ac270dc0"><gtr:id>c345338015db5b28ee186446ac270dc0</gtr:id><gtr:otherNames>McSharry BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/148291B4-DA09-4B29-9973-F20F779C167D"><gtr:id>148291B4-DA09-4B29-9973-F20F779C167D</gtr:id><gtr:title>TL1A both promotes and protects from renal inflammation and injury.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b998be4188d5c8d563cef6a1110d03e9"><gtr:id>b998be4188d5c8d563cef6a1110d03e9</gtr:id><gtr:otherNames>Al-Lamki RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/795466BD-BD96-4DC9-B7E3-BEF9FBCCF3FF"><gtr:id>795466BD-BD96-4DC9-B7E3-BEF9FBCCF3FF</gtr:id><gtr:title>An essential role for death receptor 3 in experimental autoimmune uveoretinitis.</gtr:title><gtr:parentPublicationTitle>Ocular immunology and inflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11c24c1d0733cad33b16bfea6481e351"><gtr:id>11c24c1d0733cad33b16bfea6481e351</gtr:id><gtr:otherNames>Calder CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0927-3948</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE857299-B910-4098-8F54-493D8FF03845"><gtr:id>EE857299-B910-4098-8F54-493D8FF03845</gtr:id><gtr:title>Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27f386b857f5e32f6b38b6bf2aa25fa1"><gtr:id>27f386b857f5e32f6b38b6bf2aa25fa1</gtr:id><gtr:otherNames>Siebert S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300180</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>